David Planchard, MD, PhD, is a Thoracic-oncologist, Head of the Thoracic Cancer Group in the Department of Medicine at Gustave Roussy, Villejuif, France.
With a career in lung cancer research spanning almost 30 years, his current research interests focus primarily on immunotherapy, genomic analysis (and high-throughput technologies) to drive lung cancer patients into specific targeted agents, and biomarkers for targeted treatment of bronchial cancers. Alongside this, he regularly co-directs clinical trials investigating thoracic tumors to develop a long-term clinical research strategy based on molecular screening.
David Planchard has been involved in over 100 Phase I-III trials and has published more than 160 articles in internationally renowned, peer-reviewed journals. He also coordinated the drafting of the latest European recommendations on the management of advanced non-small-cell lung cancer (ESMO guidelines) and is a member of the French-language Respiratory Society (SPLF), the French Intergroup of Thoracic Oncology (IFCT), ESMO, American Society of Clinical Oncology (ASCO) and American Association for Cancer Research (AACR).
EM-69874; Date of preparation: August 2021